Compare ProShares UltraShort Bloomberg Natural Gas ETF (KOLD) vs Moderna, Inc. (MRNA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ProShares UltraShort Bloomberg Natural Gas ETF vs Moderna, Inc. — how do they compare? ProShares UltraShort Bloomberg Natural Gas ETF trades at $28.23, while Moderna, Inc. trades at $61.6 (market cap $24.18B). The key difference: Moderna, Inc. is trading nearer its 52-week high, ProShares UltraShort Bloomberg Natural Gas ETF nearer its low. Which is the better fit depends on your goals.
| KOLD | MRNA | |
|---|---|---|
Sector | Leveraged / Inverse | Health |
52-Week High | $49.39 | $81.80 |
52-Week Low | $13.58 | $22.36 |
Market Cap | — | $24.18B |
Enterprise Value | — | $20.33B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
KOLD trades at $28.035, down 2.11% today, with technical indicators showing a bullish bias despite recent weakness. The stock faces strong resistance at $29-$30 levels while finding support at $28. Natural gas market volatility continues to drive price action, with weather forecasts and LNG export flows being key near-term catalysts. Recent news highlights steady natural gas futures trading amid mixed demand signals.
The outlook remains tactical given KOLD's leveraged exposure to natural gas price movements. Upside potential exists if weather-driven demand strengthens, but risks include production increases and storage levels. Investors should monitor EIA storage reports and global LNG demand trends for directional cues in this volatile energy sector ETF.
Moderna (MRNA) trades at $59.81, up 1.08% today, with a bullish technical signal from moving averages and recent FDA approval for its mRNA flu vaccine mFLUSIVA. Despite beating Q2 2026 EPS estimates, revenue has declined from pandemic peaks, with a net income margin of -142.58% in 2026. The stock faces resistance near $61-$63, while support lies at $56-$59.
Outlook remains mixed; pipeline advancements in flu, Ebola, and oncology offer growth potential, but persistent losses and high valuation ratios pose risks. Analyst consensus is cautious with a $54.33 price target below current levels, reflecting concerns over profitability amid transitioning business focus.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ProShares UltraShort Bloomberg Natural Gas ETF
KOLD is an inverse leveraged ETF that seeks to provide two times (2x) the inverse daily performance of the Bloomberg Natural Gas Subindex. It is designed for investors looking to profit from falling natural gas prices.
Read more on KOLD →About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →
